The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Diabetic kidney disease (DKD) is a devastating complication of diabetes, that in it's worst
form, can lead to early cardiovascular death or kidney failure. A group of medicines used to
treat diabetes, glucagon-like-peptide-1 analogues (GLP-1), may be able to protect people with
diabetes from DKD by reducing inflammation in the kidney. This study aims to test this theory
by studying the effect of GLP-1 on kidney function in people with diabetes.
To understand how GLP-1 can affect inflammation, the investigators will give a GLP-1
treatment (Liraglutide) to people with DKD and monitor the effect on inflammation and kidney
function using blood and urine tests. The investigators will compare these results to
patients with DKD who do not receive GLP-1 treatment.
If GLP-1 proves to be effective in reducing inflammation and improving kidney function, then
it could be developed as a viable new treatment for people with DKD, and may significantly
reduce the disease burden, or the risk of DKD, in people with diabetes. This would be a major
advance in the treatment of DKD.